Trump imposes tariffs on pharmaceuticals, adjusts duties on steel, other metals

President Trump announced tariffs up to 100% on some name-brand pharmaceuticals (with EU/Japan/South Korea/Switzerland set at 15% and the UK at 10%), while major drugmakers that signed confidential deals (Pfizer, Merck, Bristol Myers Squibb, AstraZeneca) are exempt and other firms can reduce duties to 20% by striking agreements. Metals rules shift tariff calculation to the full product value: products with <15% foreign steel/aluminum/copper by weight are exempt, while those >15% face a flat 25% tariff on the full value instead of a prorated basis. The changes follow a Commerce Department national-security probe of pharma supply chains and could materially affect healthcare and industrial metals sectors, with a think tank estimating the format could raise up to $70 billion in additional revenue.

Analysis

Large-cap integrated pharmas and domestic manufacturing service providers are positioned to capture the outsized structural re-shaping that follows any durable move to favor onshore production: they can internalize one-time capex, reprice commercial contracts, and win the supply contracts that flow from reshoring. Expect the winners to be CDMOs, specialty API makers, and engineering/constructors that deliver sterile-fill and small-molecule capacity; these businesses can re-rate faster than final-selling pharma margins because capacity is a scarce, high-barrier asset.

On metals, a rules-change that ties duties to transaction value shifts strategic behavior immediately — exporters change invoicing, OEMs redesign BOMs to fall below material-content thresholds, and recyclers gain pricing power where scrap effectively becomes a protected domestic feedstock. The economic transmission is multi-stage: an initial working-capital and procurement shock in the next 0–6 months, followed by a 12–36 month capex wave as firms decide whether to re-source, automate to reduce metal intensity, or accept higher input costs.

Key risks and reversals are policy, not product: litigation, administrative backtracking, or trade retaliation could unwind price effects within a single earnings cycle, while enforcement gaps could keep impacts localized. The market consensus underestimates the micro winners beyond Big Pharma — small cap CDMOs and specialty industrials — and overestimates immediate pass-through to consumer prices because large buyers will pursue long-term supplier contracts and hedges rather than transient spot passthrough.

Key Decisions for Investors

• Buy Pfizer (PFE) 9–12 month call spread (buy 6–9 month or 12-month OTM calls, sell higher strike) — thesis: large integrated player wins preferential commercial re-contracting and supply roles; risk limited to premium, target 20–35% upside on re-rating over 6–12 months.
• Long Catalent (CTLT) or Lonza-equivalent CDMO (12–24 month horizon) — implement via stock or LEAP calls; thesis: capacity owners capture margin expansion and M&A optionality as pharma onshores; downside is execution/capex miss — size position 1–3% NAV.
• Long Nucor (NUE) or US-centric steel recycler (6–12 months) — use equity or 6–9 month call options; thesis: effective protection of domestic metal value and pricing power for recyclers/primary producers; risk: administrative reversal or material redesigns compress upside.
• Event pair: long select CDMO (CTLT) / short a mid-cap import-dependent OEM (select consumer durables) for 6–12 months — captures divergence if reshoring accelerates; set stop-loss at 12–15% and target asymmetric 2:1 reward:risk on re-rating spread.